TECFIDERA (dimethyl fumarate) 120mg and 240mg delayed-release caps by Biogen Idec Biogen presented new data at ECTRIMS showing that Tecfidera (dimethyl fumarate) significantly reduced multiple ...

According to the CHMP, Tecfidera has a favorable benefit-to-risk balance based on the quality, safety and efficacy data submitted by Biogen. Results from studies showed that treatment with Tecfidera ...

Tecfidera (dimethyl fumarate) is a prescription drug used to treat multiple sclerosis (MS). Tecfidera’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

Tecfidera’s (dimethyl fumarate) usual dosage for MS and CIS is 120 mg twice per day for 7 days, and then 240 mg twice per day. Tecfidera treats the following conditions: relapsing-remitting multiple ...

U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales topping $3 ...

On April 20, 2016, at the 68th annual meeting of the American Academy of Neurology (or AAN), Biogen presented data emphasizing the real-world efficacy of Tecfidera and highlighted the improved ...

Biogen Idec raised its full-year guidance today, based largely off strong launch sales of MS pill Tecfidera. The Weston, MA, biotech brought in sales of $1.7 billion for 2Q, an increase of 21% from ...

WESTON, Mass.--(BUSINESS WIRE)-- Biogen Idec (NAS: BIIB) today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 8,399,514, which offers additional protection for ...

Biogen’s DTC ad for multiple sclerosis pill Tecfidera has garnered its fair share of criticism from patients who say it’s unrealistic. But that didn’t stop the TV commercial from getting the job done, ...

Biogen Idec to Begin Launching TECFIDERA in Initial EU Countries in the Coming Weeks CAMBRIDGE, Mass.--(BUSINESS WIRE)-- TECFIDERA® (dimethyl fumarate) has been approved by the European Commission (EC ...

Opening act Biogen's C-suite is likely smiling at its 2013 performance. Tecfidera blunts a lot of the risk tied to slowing sales for the company's $3 billion-a-year Avonex. That drug faces stiff ...

A decision to put off the launch of Biogen's (BIIB) highly anticipated launch of its MS drug Tecfidera in Europe appears to have paid off, thanks to expanded patent protection. Rapidly growing demand ...